Quenon, Lisa
Collij, Lyduine E.
Garcia, David Vállez
Lopes Alves, Isadora
Gérard, Thomas
Malotaux, Vincent
Huyghe, Lara
Gispert, Juan Domingo
Jessen, Frank
Visser, Pieter Jelle
den Braber, Anouk
Ritchie, Craig W.
Boada, Mercè
Marquié, Marta
Vandenberghe, Rik
Luckett, Emma S.
Schöll, Michael
Frisoni, Giovanni B.
Buckley, Christopher
Stephens, Andrew
Altomare, Daniele
Ford, Lisa
Birck, Cindy
Mett, Anja
Gismondi, Rossella
Wolz, Robin
Grootoonk, Sylke
Manber, Richard
Shekari, Mahnaz
Lhommel, Renaud
Dricot, Laurence
Ivanoiu, Adrian
Farrar, Gill
Barkhof, Frederik
Hanseeuw, Bernard J.
,
Funding for this research was provided by:
Innovative Medicines Initiative 2 Joint Undertaking (115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952, 115952)
SAO-FRA (2022/0026, 2022/0026)
Fonds De La Recherche Scientifique - FNRS (ASP40001776, ASP32921248, CCL grant #40010417)
Article History
Received: 1 February 2024
Accepted: 9 June 2024
First Online: 17 June 2024
Declarations
:
: The AMYPAD project was reviewed and approved by Medical Ethical Committee of the University Medical Center Amsterdam, location VUmc and all local sites. The AMYPAD PNHS is registered on the EU Clinical Trials Register [22] with the EudraCT Number: 2018-002277-22. The study was conducted following the Protocol and the Declaration of Helsinki and Good Clinical Practice. All patients/participants provided written informed consent to participate in this study.
: Not applicable.
: LEC has received research support from GE Healthcare (paid to institution).JG has received research support from GE Healthcare, Roche Diagnostics, F. Hoffmann – La Roche and speaker’s fees from Biogen and Philips. In addition, he holds a “Ramón y Cajal” fellowship (RYC-2013-13054), has received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD grant agreement no 115952, and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261).FJ received payment/honoraria from Roche and Lilly. He has participated on a Data Safety Monitoring Board or Advisory Board for AC Immune, Biogen, Roche, Eisai, and Grifols.PV has served as member of the advisory board of Roche Diagnostics and received nonfinancial support from GE Healthcare, research support from Biogen and grants from Bristol-Myers Squibb, EU/EFPIA Innovative Medicines Initiative Joint Undertaking, EU Joint Programme– Neurodegenerative Disease Research (JPND and ZonMw).LF is an employee of Janssen Pharmaceuticals. Mark Schmidt is an employee of Janssen Pharmaceuticals.CR has received fees for contributions to Advisory Boards from Biogen, Eisai, Eli Lilly, Roche, Roche Diagnostics, Actinogen, Alchemab, Merck, Kyowa Kirin, and Signant. His research has been supported by Janssen and Biogen. He was Chief Investigator of the IMI Funded EPAD project that had multiple EFPIA and SME partners.MB has received funding support from the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER - Una manera de hacer Europa) grant PI17/01474. MB has consulted for Araclon, Avid, Grifols, Lilly, Nutricia, Roche, Eisai and Servier. She received fees from lectures and funds for research from Araclon, Biogen, Grifols, Nutricia, Roche and Servier. She reports grants/research funding from Abbvie, Araclon, Biogen Research Limited, Bioiberica, Grifols, Lilly, S.A, Merck Sharp & Dohme, Kyowa Hakko Kirin, Laboratorios Servier, Nutricia SRL, Oryzon Genomics, Piramal Imaging Limited, Roche Pharma SA, and Schwabe Farma Iberica SLU.MM has received funding support from the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER - Una manera de hacer Europa) grant PI19/00335. MM has consulted for F. Hoffmann-La Roche Ltd. and was part of the Spanish Scientific Advisory Board for biomarkers o Araclon biotech.RV institution has Clinical Trial Agreements (RV as PI) with Alector, Biogen, Janssen Pharmaceuticals, NovoNordisk, Prevail, Roche, UCB. RV’s institution has consultancy agreements (RV as DSMB member) with AC Immune and Novartis. RV was global PI of the Phase 1 and 2 18F-flutemetamol trials. RV’s institution had a material transfer agreement (RV as PI) with GEHC for free tracer delivery of the FPACK cohort baseline scans and with Avid Pharmaceuticals, an EliLilly subsidiary. AD Research support: Siemens Healthineers, Life Molecular Imaging, GE Healthcare, AVID Radiopharmaceuticals, Sofie, Eisai, Novartis/AAA. Speaker Honorary/Advisory Boards: Siemens Healthineers, Sanofi, GE Healthcare, Biogen, Novo Nordisk, Invicro, Novartis/AAA, Bayer Vital. Stock: Siemens Healthineers, Lantheus Holding. Patents: Patent pending for 18F-PSMA7 (PSMA PET imaging tracer).MS has received fees for contributions to Advisory Boards from Biogen, Eisai, Eli Lilly, Roche, Roche Diagnostics, Actinogen, Alchemab, Merck, Kyowa Kirin and Signant. His research has been supported by Janssen and Biogen. He was Chief Investigator of the IMI Funded EPAD project that had multiple EFPIA and SME partners.GBF reports grants from Avid Radiopharmaceuticals, Biogen, GE International, Guerbert, IXICO, Merz Pharma, Nestlé, Novartis, Eisai, Piramal, Roche, Siemens, Teva Pharmaceutical Industries, and Vifor Pharma; he has received personal fees from AstraZeneca, Avid Radiopharmaceuticals, Biogen, Roche, Diadem, Neurodiem, Elan Pharmaceuticals, GE International, Lundbeck, Pfizer, and TauRx Therapeutics.AS and RG are employees of Life Molecular Imaging GmbH.GF is an employee of GE Healthcare.FB Steering committee or iDMC member for Biogen, Merck, Roche, EISAI and Prothena. Consultant for Roche, Biogen, Merck, IXICO, Jansen, Combinostics. Research agreements with Merck, Biogen, GE Healthcare, Roche. Co-founder and shareholder of Queen Square Analytics LTD.BJH received consulting fees from Biogen, Roche and Eisai (paid to institution).The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.